drug
as of 2026-07-01ALKS 3831
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Alkermes, Inc.
6 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
6
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
NCT03201757Phase 3Completed
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
NCT03187769Phase 3Completed
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02873208Phase 3Completed
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
NCT02694328Phase 3Completed
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02669758Phase 3Completed
A Phase 1 Safety Study in Adults With Schizophrenia
NCT02804568Phase 1Completed
KOLs & investigators
2
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
trial
indication
indication
indication
indication
indication
KOL
David McDonnell, MD
personKOL score 8
Alkermes Medical Director, MD
personKOL score —